Zacks Research Has Negative Outlook of Chemours Q3 Earnings

The Chemours Company (NYSE:CC - Free Report) - Stock analysts at Zacks Research reduced their Q3 2026 EPS estimates for Chemours in a research report issued on Monday, May 19th. Zacks Research analyst R. Department now forecasts that the specialty chemicals company will post earnings per share of $0.74 for the quarter, down from their previous forecast of $0.78. The consensus estimate for Chemours' current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours' Q4 2026 earnings at $0.45 EPS.

A number of other research analysts have also issued reports on CC. Barclays lowered their target price on Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a report on Tuesday, April 1st. Mizuho set a $15.00 target price on shares of Chemours in a report on Tuesday, April 15th. Truist Financial reduced their target price on shares of Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a report on Monday, April 14th. Morgan Stanley dropped their price target on Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. Finally, The Goldman Sachs Group cut their price objective on Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a research report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Chemours has a consensus rating of "Hold" and a consensus price target of $17.56.

Chemours Stock Down 5.4%

CC opened at $10.57 on Thursday. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68. The company has a market capitalization of $1.58 billion, a PE ratio of 18.54 and a beta of 1.76. The stock's fifty day moving average is $12.13 and its 200-day moving average is $16.15. Chemours has a one year low of $9.33 and a one year high of $27.65.

Chemours (NYSE:CC - Get Free Report) last released its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). Chemours had a return on equity of 26.54% and a net margin of 1.51%. The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same quarter last year, the company earned $0.32 earnings per share. The business's revenue for the quarter was up .4% on a year-over-year basis.

Chemours Announces Dividend

The company also recently disclosed a dividend, which will be paid on Monday, June 16th. Investors of record on Monday, May 19th will be paid a $0.0875 dividend. This represents a yield of 3.17%. The ex-dividend date is Friday, May 16th. Chemours's dividend payout ratio is 175.00%.

Insiders Place Their Bets

In other Chemours news, CFO Shane Hostetter acquired 4,450 shares of the firm's stock in a transaction on Monday, May 19th. The stock was purchased at an average cost of $11.28 per share, for a total transaction of $50,196.00. Following the transaction, the chief financial officer now owns 59,694 shares of the company's stock, valued at $673,348.32. The trade was a 8.06% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.47% of the company's stock.

Institutional Trading of Chemours

A number of hedge funds have recently made changes to their positions in the stock. Corient Private Wealth LLC raised its holdings in Chemours by 4.7% during the fourth quarter. Corient Private Wealth LLC now owns 13,428 shares of the specialty chemicals company's stock valued at $227,000 after buying an additional 604 shares in the last quarter. HUB Investment Partners LLC increased its holdings in shares of Chemours by 1.4% during the 4th quarter. HUB Investment Partners LLC now owns 58,250 shares of the specialty chemicals company's stock valued at $984,000 after acquiring an additional 821 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Chemours by 73.9% during the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after acquiring an additional 948 shares during the last quarter. Itau Unibanco Holding S.A. raised its stake in shares of Chemours by 39.3% in the 4th quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock valued at $60,000 after acquiring an additional 1,003 shares in the last quarter. Finally, ARGA Investment Management LP lifted its holdings in Chemours by 0.7% in the 4th quarter. ARGA Investment Management LP now owns 148,614 shares of the specialty chemicals company's stock worth $2,512,000 after purchasing an additional 1,032 shares during the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.